Literature DB >> 29107270

Prediagnostic Risk Assessment with Prostate MRI and MRI-Targeted Biopsy.

Marc A Bjurlin1, Samir S Taneja2.   

Abstract

Prostate MRI is commonly used in the detection of prostate cancer to reduce the detection of clinically insignificant disease; maximize the detection of clinically significant cancer; and better assess disease size, grade, and location. The clinical utility of MRI seems to apply to men with no prior biopsy, who have had a previous negative biopsy, and men who are candidate for active surveillance. In conjunction with traditional clinical parameters and secondary biomarkers, MRI may allow more accurate risk stratification and assessment of need for prostate biopsy.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  MRI; MRI-ultrasonography fusion; Prebiopsy; Risk assessment; Targeted biopsy

Mesh:

Year:  2017        PMID: 29107270     DOI: 10.1016/j.ucl.2017.07.012

Source DB:  PubMed          Journal:  Urol Clin North Am        ISSN: 0094-0143            Impact factor:   2.241


  2 in total

1.  Integration of magnetic resonance imaging into prostate cancer nomograms.

Authors:  Garrett J Brinkley; Andrew M Fang; Soroush Rais-Bahrami
Journal:  Ther Adv Urol       Date:  2022-05-13

2.  Is Additional Systematic Biopsy Necessary in All Initial Prostate Biopsy Patients With Abnormal MRI?

Authors:  Xueqing Cheng; Jinshun Xu; Yuntian Chen; Zhenhua Liu; Guangxi Sun; Ling Yang; Jin Yao; Hao Zeng; Bin Song
Journal:  Front Oncol       Date:  2021-02-26       Impact factor: 6.244

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.